FDA Clearance Tracker · P120008-S022
ARCHITECT AFP, Alinity i AFP
Last checked: Nov 20, 2026Latest source record: Oct 11, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Oct 11, 2023
Approved
Time to decision
237 days
Received Feb 16, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P120008-S022
- Device name
- ARCHITECT AFP, Alinity i AFP
- Applicant
- Abbott Laboratories
- Applicant location
- Abbott Park, IL
- Received
- Feb 16, 2023
- Decided
- Oct 11, 2023
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P120008
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for the formulation change for the common accessories, Pre-Trigger and Trigger, and storage condition changes for Pre-Trigger used on ARCHITECT i2000SR, ARCHITECT i1000SR and Alinity i analyzer
Source documents
Other decisions for Abbott Laboratories
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Anti-HCV Next510(k)
K262156 · Decided Sep 23, 2026 · 89 days after receipt
Device type: Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus (MZO) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.